Navigation Links
Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
Date:6/19/2008

AstraZeneca's CEO to be Deposed in London on Friday, June 20, 2008

NEW YORK, June 19 /PRNewswire/ -- Weitz & Luxenberg, PC, one of the leading plaintiffs' litigation law firms in America, filed a lawsuit today against pharmaceutical giant AstraZeneca on behalf of a New York City Fire Department Emergency Medical Technician whose diabetes was allegedly caused by AstraZeneca's drug Seroquel. The plaintiff, EMT Ernest Armstead, was one of the many brave responders on the morning of September 11, 2001. He was severely injured when the World Trade Center's North Tower collapsed as he was helping victims at the foot of the buildings.

Suffering from Post-Traumatic Stress Disorder after recovery from his 9/11 physical injuries, Mr. Armstead was prescribed Seroquel, which Weitz & Luxenberg claims did not carry a warning that the powerful drug can cause diabetes. He thereafter developed the debilitating, life-long disease known as Type 2 diabetes. Mr. Armstead joins thousands of others across the country who has filed actions claiming that Seroquel caused them to develop diabetes and that AstraZeneca hid its knowledge of this risk from the FDA, doctors and patients.

In a letter dated November 16, 2006, the Department of Health and Human Services of the Food and Drug Administration cited violations of the Federal Food, Drug, and Cosmetic Act in connection with AstraZeneca's use of promotional material deemed by the FDA to be "false or misleading because it minimizes the risk of hyperglycemia and diabetes mellitus" and which "raises significant public health and safety concerns through its minimization of the risks associated with Seroquel."

A deposition of AstraZeneca's Chief Executive Officer, David Brennan, about his company's alleged undisclosed knowledge regarding the dangerous side effect of diabetes, is being taken this Friday, June 20th in London, England at the law offices of Baker Botts, a U.S. firm defending the company. Lawyers fr
'/>"/>

SOURCE Weitz & Luxenberg, PC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genzyme Files Applications for Approval of Mozobil in the United States and Europe
2. Jazz Pharmaceuticals Files Form S-3 Registration Statements
3. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
4. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
5. Immunosyn Corporation Files 10-Q
6. Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance
7. Benda Pharmaceutical Files Amendment To Form S-1
8. Oncothyreon files investigational new drug application for PX-866 oncology compound
9. Vion Pharmaceuticals Files Plan With Nasdaq
10. NeoGenomics Files Annual Report on Form 10-KSB with the SEC
11. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas City Animal ... and animal health companies to hear from animal health companies with the newest ... received licensing agreements or distribution contracts. This meeting is one of the ...
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ ... company in the emerging field of regenerative medicine, today ... two investor conferences in the month of September.  ... Officer, will present at Rodman & Renshaw,s 17th Annual ... 10:25am ET/7:25am PT at the St. Regis Hotel in ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER ... expertly narrows down the product choices to a manageable shortlist of bench and ... list to models that fit best with the customer’s industry and application. ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2METTLER TOLEDO Updates Online Scale Selection Tool 2
... SAN DIEGO, Oct. 20 Cardium Therapeutics,(Amex: ... Inc., announced,today that it has received 510(k) clearance ... market the RapidBlue(TM) System, an endovascular,temperature modulation device. ... to manage and control patient body temperature.,This new ...
... joins Pierpoint International as Global VP of Recruitment Operations and Diversity ... ... -- Pierpoint International is pleased to announce the appointment of Robert ... most recently served as AVP of Staffing and Diversity for USAA, ...
... TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ) today announced ... a Phase I multiple dose clinical trial of NGX426, ... The trial is,designed to evaluate the safety, tolerability and ... days. NGX426 has been,safely administered to more than 150 ...
Cached Biology Technology:Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 2Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 3Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 4Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 5Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 6Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 7Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 8Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 9Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 10Robert Cantu Appointed Vice President of Pierpoint International 2TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 2TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 3TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 4
(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
(Date:8/5/2015)... According to a new market ... Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, ... to 2020", published by MarketsandMarkets, defines and segments the ... segments. The global PIAM Market is estimated to grow ... 2019, at a CAGR of 14.9 % from 2014 ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... athletes looking to boost performance comes in the form of ... for its popularity is twofold says Scott Forbes, a doctoral ... for nitric oxide that is known to improve blood flow, ... to working muscles and assist with metabolic waste product removal. ...
... Bethesda, MD The Association for Molecular Pathology ... to exclusively license the subject matter of a cancer-related ... written remarks were submitted to NIH in response to ... entitled, "Prospective Grant of Exclusive License: The Development of ...
... of engineering principles to understand and treat medical conditions ... damage to the brain caused by a traumatic injury. ... presented in a special issue of Journal of ... Liebert, Inc. ( http://www.liebertpub.com ) The entire issue is ...
Cached Biology News:L-arginine: Supplement tested on fit, athletic men shows no advantage 2L-arginine: Supplement tested on fit, athletic men shows no advantage 3AMP opposes exclusive licensing of NIH proteomics patent 2Bioengineering yields new approaches for diagnosing and treating traumatic brain injury 2
The 12-Tube Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 12 microcentrifuge tubes. ,Magnets: Neodymium rare earth permanent ma...
DONOR BOVINE SERUM AND PLASMA...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
...
Biology Products: